Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PTPN13
REST API REST API
Homo sapiens
PTPN13 is differentially expressed in 236 experiments: 126 organism parts: liver, ovary, ... (124 more);, 155 disease states: normal, chronic myelogenous leukemia, ... (153 more);, 73 cell types 405 cell lines 30 compound treatments and 63 other conditions.
Synonyms PTP-BAS, PTP-BL, PTPL1, PTP1E
Orthologs PTPN13 (Gallus gallus)   ptpn13 (Danio rerio)   Ptpn13 (Mus musculus)   Ptpn13 (Rattus norvegicus)   ptpn13 (Xenopus laevis)   PTPN13 (Bos taurus)   Q9BEF9_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, phosphatase activity, protein binding, cytoskeleton, cytoplasm, dephosphorylation, protein tyrosine phosphatase activity, neuron projection, nucleus, hydrolase activity, peptidyl-tyrosine dephosphorylation, protein dephosphorylation, cell body
InterPro Term Tyr_Pase_cat, PDZ/DHR/GLGF, FERM_central, Band_41_domain, KIND, Tyr_Pase_rcpt/non-rcpt, FERM_domain, Tyr_Pase_non-rcpt_typ-13, Band_41_fam, FERM_N, FERM_PH-like_C, Tyr/Dual-specificity_Pase
UniProt Accession Q4W5F5, D6R9M4, D6R9X4, Q12923
Search EB-eye ENSG00000163629
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-7540, E-GEOD-3526, ... (26 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (41 experiments)

Factor Value U/D Experiments
HL-60
3
E-GEOD-5258, E-GEOD-24147, E-MTAB-37
MCF-7
3
E-GEOD-20081, E-GEOD-3529, E-GEOD-19639
H1
2
E-GEOD-1309, E-MTAB-62
U87
2
E-MEXP-903, E-GEOD-20089
A549
2
E-GEOD-3202, E-GEOD-6013
K562
2
E-MTAB-37, E-GEOD-24147
399 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-MEXP-66, E-GEOD-20677, ... (35 experiments)

Factor Value U/D Experiments
induced pluripotent stem cell
2
E-GEOD-18265, E-GEOD-18147
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
stromal cell
2
E-GEOD-1460, E-GEOD-3998
CD34 positive
1
E-GEOD-12662
BDCA3+ dendritic cell
1
E-TABM-34
human foreskin fibroblast
1
E-GEOD-18265
67 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-2508, E-GEOD-2466, E-MEXP-1121, ... (40 experiments)

Factor Value U/D Experiments
cervical carcinoma
3
E-MTAB-37, E-MEXP-1331, E-MTAB-62
prostate carcinoma
3
E-GEOD-96, E-MTAB-62, E-MEXP-2034
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-96
control
2
E-GEOD-21912, E-GEOD-16363
glioblastoma
2
E-GEOD-4290, E-MTAB-37
neuroblastoma
1
2
E-MTAB-37, E-GEOD-1825, E-MTAB-62
149 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-6907, E-GEOD-15205, E-GEOD-5824, E-GEOD-6462, ... (19 experiments)

Factor Value U/D Experiments
glutamine
2
E-MEXP-1335, E-MEXP-941
none
2
3
E-GEOD-412, E-GEOD-5824, E-GEOD-20719, E-GEOD-7307, E-MEXP-2285 ... (5 experiments)
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
actinomycin D
1
E-GEOD-6400
bis [(+)-tartrato] diantimonate (III) dipotassium trihydrate
1
E-GEOD-6907
TGF
1
E-GEOD-15205
24 more value(s).


Age at onset

studied in E-GEOD-21521

Factor Value U/D Experiments
LT6
1
E-GEOD-21521


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-2034, E-GEOD-21589, ... (8 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-5999, E-GEOD-20033, E-MEXP-2359, E-MEXP-2283, E-MTAB-62 ... (5 experiments)

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-21138, E-GEOD-21887, ... (7 experiments)

Environmental stress
studied in E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (8 experiments)

Genotype
studied in E-GEOD-1923, E-GEOD-2466, E-GEOD-17476, E-GEOD-1153, E-GEOD-17347, ... (6 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-13073, E-MEXP-2657, E-TABM-127, E-GEOD-20540, E-GEOD-9764, ... (6 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-740, E-GEOD-2466, E-MEXP-2069, ... (27 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-9723, E-GEOD-17400

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Organism
studied in E-AFMX-1

Organism status
studied in E-GEOD-19188

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phenotype
studied in E-GEOD-22309, E-GEOD-21750, E-GEOD-17636, E-GEOD-2487

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

Qrt pcr areg dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-18791

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-18995

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-4883

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Treatment
studied in E-GEOD-15799

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-TABM-147

Tumor size
studied in E-GEOD-8167

Vehicle
studied in E-GEOD-5258

Processing time: 0.371 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM